Trimethoprim‐Sulfamethoxazole as Toxoplasmosis Prophylaxis for Heart Transplant Recipients
Open Access
- 1 April 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (7) , 932-933
- https://doi.org/10.1086/368209
Abstract
Sir—Toxoplasmosis is a disease that is highly transmissible to D+/R- patients (i.e., patients who are seronegative for Toxoplasma gondii IgG antibodies and who receive a heart transplant from donors who are seropositive for T. gondii IgG antibodies). This disease, along with disseminated aspergillosis, is associated with the highest mortality rate attributable to an infectious complication in heart transplant recipients. For these high-risk patients, 25 mg of pyrimethamine is given as toxoplasmosis prophylaxis for 6 weeks after surgery [1–3].Keywords
This publication has 4 references indexed in Scilit:
- Infectious Complications among 620 Consecutive Heart Transplant Patients at Stanford University Medical CenterClinical Infectious Diseases, 2001
- Disseminated Toxoplasmosis after Liver TransplantationClinical Infectious Diseases, 1999
- Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 yearsJournal of Infection, 1994
- Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patientsTransplant International, 1992